<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03470701</url>
  </required_header>
  <id_info>
    <org_study_id>2017-0516</org_study_id>
    <nct_id>NCT03470701</nct_id>
  </id_info>
  <brief_title>Improving Albuminuria Screening Compliance Using a Smartphone Urinalysis Kit</brief_title>
  <official_title>Improving Albuminuria Screening Compliance Using a Smartphone Urinalysis Kit in the Hypertensive Non-Diabetic Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Geisinger Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Kidney Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Healthy.io Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Geisinger Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the effectiveness of mailed, smartphone urinalysis kits to improve
      albuminuria screening compliance and detection of albuminuria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This proposal will examine the effect of mailed, smartphone urinalysis kits to improve
      albuminuria screening compliance and detection of albuminuria. The investigators will
      randomize 1,000 non-diabetic MyGeisinger portal users with hypertension and last clinic blood
      pressure &gt;= 130/80 mmHg who have not received albuminuria screening to either: 1) control -
      usual care or 2) intervention - mailed urinalysis smartphone kit. All patients will first
      receive a reminder letter to have albuminuria screening completed at their clinic in
      coordination with the Geisinger Care Gap Team. Patients randomized to the intervention arm
      who do not complete this initial screening test will then be offered a mailed, smartphone
      urinalysis testing kit. Patients with 1+ or greater detected urine protein will be
      recommended to have urine albumin/creatinine ratio (ACR) testing to confirm albuminuria.
      Patients with ACR &gt;= 30 mg/g will be referred to pharmacists for optimal treatment of
      albuminuria (ACE or ARB, statin, BP goal &lt;130/90 mmHg).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Completion of albuminuria screening</measure>
    <time_frame>Baseline to 3 months of enrollment date</time_frame>
    <description>Includes completion of mailed smartphone urinalysis and clinical labs (urinalysis, albumin/creatinine ratio, or protein/creatinine ratio)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total number of detected albuminuria cases</measure>
    <time_frame>Baseline to 3 months of enrollment date</time_frame>
    <description>confirmed by urine albumin/creatinine ratio &gt;= 30 mg/g</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Achievement of optimal albuminuria treatment</measure>
    <time_frame>Baseline to 3 months of enrollment date</time_frame>
    <description>Among patients with newly detected albuminuria, we will examine whether achievement of optimal albuminuria treatment (ACE or ARB, statin, BP goal &lt;130/80 mmHg) improves at 3 months compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Albuminuria</condition>
  <condition>Chronic Kidney Diseases</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Control - usual care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This arm will receive usual care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mailed Urinalysis Smartphone Kit</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will receive a mailed urinalysis smartphone kit if they do not complete albuminuria screening after the initial reminder to do so.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mailed Urinalysis Smartphone Kit</intervention_name>
    <description>Patients who fail to complete albuminuria screening after the initial reminder to do so, will be contacted by phone and offered a mailed smartphone urinalysis kit. Agreeable patients will then receive the mailed kit and instructions to use their smartphone camera to analyze a urine dipstick.</description>
    <arm_group_label>Mailed Urinalysis Smartphone Kit</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 and older

          -  Hypertension

          -  Last outpatient BP â‰¥ 130/80 mmHg

          -  Active MyGeisinger users with a listed mobile phone number

          -  Has a Geisinger PCP and followed by the Care Gaps team

          -  No prior urine albuminuria test (urine dipstick, albumin/creatinine ratio,
             protein/creatinine ratio)

        Exclusion Criteria:

          -  History of diabetes

          -  Receiving dialysis

          -  History of kidney transplant

          -  eGFR &lt; 15 ml/min/1.73m2

          -  Principal investigator or PCP discretion (i.e. concerns about safety, compliance)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alex R Chang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Geisinger Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alex R Chang, MD</last_name>
    <phone>570-214-9825</phone>
    <email>achang@geisinger.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christina Yule, BS</last_name>
    <phone>570-214-5233</phone>
    <email>cmyule@geisinger.edu</email>
  </overall_contact_backup>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2018</study_first_submitted>
  <study_first_submitted_qc>March 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2018</study_first_posted>
  <last_update_submitted>March 19, 2018</last_update_submitted>
  <last_update_submitted_qc>March 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Geisinger Clinic</investigator_affiliation>
    <investigator_full_name>Alexander Chang</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Albuminuria</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

